AX-2026-042332 · Tirzepatide · TFC lot TFC-2508-L2482

Section 1

Results

Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 25 min gradient, 214 nm	98.40	% area	≥ 97.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	1.60	% area	≤ 3.0	PASS
Largest single impurity	RP-HPLC — des-Gly deletion (−57 Da)	0.82	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	4810.4103	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, unit resolution (single quadrupole)	4810.4926	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+17.1	ppm	± 15	FAIL
Total peptide content	by difference from the gravimetric mass balance	89.37	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	87.94	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	5.69	mg	5 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	5.004	mg	5 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	100.1	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	1.68	%	≤ 8.0	PASS
Counter-ion (TFA)	anion-exchange ion chromatography	8.23	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.72	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.48	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	2.98	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 25 min gradient	16.84	min	16.81 ± 0.45 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	0.98	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	31,340	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Aib13]-diastereomer	0.41	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 25 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 31,340, and skew follows the reported asymmetry factor of 0.98. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.82 % impurity against a 98.40 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Tirzepatide — main peak	16.84	4,782,545	98.40	—
2	des-Gly deletion (−57 Da)	16.33	39,855	0.82	-57.021
3	C20 diacid mono-amide	18.19	22,843	0.47	+0.984
4	des-Aib2 analogue	16.55	7,776	0.16	-85.053
5	Met(O) sulfoxide (+16 Da)	16.22	4,860	0.10	+15.995
6	[D-Aib13]-diastereomer	16.68	1,458	0.03	0.000
7	trifluoroacetyl adduct (+96 Da)	17.61	972	0.02	+95.982
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 4810.4103 Da, computed from C225H348N48O68. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, unit-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 4810.4926 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
7+	688.2087	688.2205	0.0118	8.7
6+	802.7423	802.7560	0.0137	49.9
5+	963.0893	963.1058	0.0165	100.0
4+	1203.6099	1203.6304	0.0205	53.8
3+	1604.4774	1604.5048	0.0274	8.7

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	1.68
Counter-ion (TFA)	ion chromatography	8.23
Residual solvent + inorganic residue	estimated	0.72
Total peptide content	by difference	89.37
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.27	98.40	divergence +0.12 pp vs batch median
Total impurities (% area)	not stated	1.60
Largest single impurity (% area)	not stated	0.82
Water (%)	0.6	1.68
Counter-ion (%)	not stated	8.23
Peptide content (%w/w)	not stated	89.37
Endotoxin (EU/mg)	0.29	0.48
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (−20 °C, 2 d) → laboratory (courier, dry ice, 3 d) → assay.
Assay date: 09 Jan 2026
Submitted to the index: 02 Feb 2026
Laboratory: Medutest, Ljubljana, Slovenia
Method basis: 25 min gradient · unit-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

That the compound is not a near-isobaric alternative. Identity was confirmed at unit mass resolution, which cannot exclude species differing by 1 or 2 Da. The specific alternatives not excluded are named in the identity block above.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 4

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

units_pedant02 Feb 2026

Half of all mass disputes are unit errors. Daltons against atomic mass units, average against monoisotopic, ppm against millidaltons: check which pair is on the report before reading +17.1 ppm as a discrepancy.

charge_envelope02 Feb 2026

The envelope on this record spans enough charge states to support a deconvolution. Where it does not, the algorithm extrapolates and the reported mass acquires an error with no physical cause at all.

chain_custody02 Feb 2026

Custody from checkout to injection is documented on this record. Provenance plus custody is what makes a single result generalise past the vial it came from.

peak_integrator02 Feb 2026

Two laboratories with different gradients will resolve a close pair differently and report two honest, different purities. Neither is wrong and the difference is not a disagreement about the material.

Section 7

Related records

Same batch — lot TFC-2508-L2482 n=8

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042330	TFC-2508-L2482	VendorInvestigate	2026-Q1	97.86	2.36	98.0	Buyer-sourced	0	PASS
AX-2026-042331	TFC-2508-L2482	Janoshik	2026-Q1	98.04	1.67	101.1	Buyer-sourced	1	FAIL
AX-2026-042333	TFC-2508-L2482	Janoshik	2026-Q1	98.16	1.86	—	Buyer-sourced	0	PASS
AX-2026-042334	TFC-2508-L2482	Janoshik	2026-Q1	98.14	1.34	98.2	Buyer-sourced	1	FAIL
AX-2026-042335	TFC-2508-L2482	Janoshik	2026-Q1	98.22	1.30	—	Buyer-sourced	0	PASS
AX-2026-042336	TFC-2508-L2482	Janoshik	2026-Q1	98.04	1.75	103.7	Buyer-sourced	0	PASS
AX-2026-042337	TFC-2508-L2482	Janoshik	2026-Q1	98.46	2.04	—	Buyer-sourced	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Tirzepatide records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-043288	CPC	CPC-2607-L1516	Janoshik	2026-Q3	96.89	5.11	101.1	Laboratory-retained	FAIL
AX-2026-041610	FGP	FGP-2603-L7753	Janoshik	2026-Q3	98.81	2.45	101.0	Buyer-sourced	PASS
AX-2026-041974	AMB	AMB-2603-C5112	Nordanalyt	2026-Q3	98.20	3.41	—	Buyer-sourced	PASS
AX-2026-041975	AMB	AMB-2603-C5112	Medutest	2026-Q3	97.88	3.45	106.9	Laboratory-retained	PASS
AX-2026-041609	FGP	FGP-2603-L7753	Janoshik	2026-Q3	98.52	2.00	98.0	Buyer-sourced	PASS
AX-2026-041978	AMB	AMB-2603-C5112	Janoshik	2026-Q3	97.94	3.57	103.0	Buyer-sourced	PASS
AX-2026-041982	AMB	AMB-2603-C5112	Janoshik	2026-Q3	97.60	4.46	—	Buyer-sourced	PASS
AX-2026-043286	CPC	CPC-2607-L1516	Kestrel	2026-Q3	98.20	4.56	—	Buyer-sourced	PASS

Other recent TFC records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042265	Humanin (HNG)	TFC-2605-U1300	PeptideMeter	2026-Q3	99.52	6.31	—	Buyer-sourced	0	PASS
AX-2026-042222	SS-31 (Elamipretide)	TFC-2607-R9099	VendorInvestigate	2026-Q3	99.46	5.41	102.6	Buyer-sourced	0	PASS
AX-2026-042236	Humanin (HNG)	TFC-2608-S9940	Nordanalyt	2026-Q3	98.64	1.80	—	Buyer-sourced	0	PASS
AX-2026-042282	Retatrutide	TFC-2608-J1156	Janoshik	2026-Q3	98.54	4.27	—	Buyer-sourced	0	PASS
AX-2026-042226	SS-31 (Elamipretide)	TFC-2607-R9099	Janoshik	2026-Q3	99.62	5.47	—	Buyer-sourced	0	PASS
AX-2026-042217	Semaglutide	TFC-2604-X9037	PeptideMeter	2026-Q3	98.95	4.61	96.9	Buyer-sourced	0	PASS
AX-2026-042339	Sermorelin	TFC-2605-Y2176	Kestrel	2026-Q3	99.93	4.14	—	Supplier-supplied	1	FAIL
AX-2026-042214	Semaglutide	TFC-2604-X9037	Kestrel	2026-Q3	99.87	4.66	103.1	Laboratory-retained	0	PASS